



REGULATED INFORMATION • REGULATED INFORMATION • REGULATED INFORMATION

ANNUAL REPORT ON THE LIQUIDITY CONTRACT

Paris and Boston, January 25, 2018 - NEOVACS (Euronext Growth : ALNEV) releases its annual report on the liquidity contract signed with Kepler Cheuvreux.

The liquidity account had the following holdings as of december 31, 2018:

- 894,000 shares
- € 71,044.44

For the prior (December 31, 2017), the corresponding figures were:

- 522 521 shares
- € 146,485.21

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com